MedTrace Logo

Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

NCT04501497 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1221

Last updated 2024-04-02

No results posted yet for this study

Summary

This is a multi-center observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer(NSCLC) or extensive disease small cell lung cancer(ED-SCLC). 800 patients in NSCLC cohort and 400 patients in ED-SCLC cohort will be enrolled in this trial to assess the efficacy and safety of this combination.

Conditions

Sponsors & Collaborators

  • Japan Lung Cancer Society

    collaborator OTHER

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Akihiko GENMA · Nippon Medical School Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-21
Primary Completion
2023-02-03
Completion
2023-02-03

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501497 on ClinicalTrials.gov